Cover Image
市場調查報告書

登革熱:開發中產品分析

Dengue Fever - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363105
出版日期 內容資訊 英文 208 Pages
訂單完成後即時交付
價格
Back to Top
登革熱:開發中產品分析 Dengue Fever - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 208 Pages
簡介

本報告提供登革熱治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

登革熱概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

登革熱:企業開發中的治療藥

登革熱:大學/機關研究中的治療藥

登革熱:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

登革熱:企業開發中的產品

登革熱:大學/機關研究中的產品

登革熱治療藥的開發企業

  • Abivax S.A.
  • Agilvax, Inc.
  • Altravax, Inc.
  • Arbovax, Inc.
  • BCI Pharma
  • Bioneer Corporation
  • Biotron Limited
  • CalAsia Pharmaceuticals, Inc.
  • Cocrystal Pharma, Inc.
  • Codagenix, Inc.
  • Emergent BioSolutions Inc.
  • Ennaid Therapeutics, LLC
  • GlaxoSmithKline Plc
  • Globavir Biosciences, Inc.
  • Hawaii Biotech, Inc.
  • Humabs BioMed SA
  • Immunotope, Inc.
  • Immunovaccine, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Kineta, Inc.
  • Merck & Co., Inc.
  • Molplex Ltd.
  • NanoViricides, Inc.
  • Novartis AG
  • NovaTarg Therapeutics, Inc
  • Panacea Biotec Limited
  • ProtInhi B.V.
  • Sanofi Pasteur SA
  • Sarepta Therapeutics, Inc.
  • SIGA Technologies, Inc.
  • 武田藥品工業
  • TechnoVax, Inc.
  • Themis Bioscience GmbH
  • VaxInnate Corporation
  • Visterra, Inc.

登革熱:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

登革熱:暫停中的計劃

登革熱:中止開發的產品

登革熱:產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8163IDB

Summary

Global Markets Direct's, 'Dengue Fever - Pipeline Review, H1 2016', provides an overview of the Dengue Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dengue Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dengue Fever
  • The report reviews pipeline therapeutics for Dengue Fever by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Dengue Fever therapeutics and enlists all their major and minor projects
  • The report assesses Dengue Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Dengue Fever

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Dengue Fever
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dengue Fever pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Dengue Fever Overview
  • Therapeutics Development
    • Pipeline Products for Dengue Fever - Overview
    • Pipeline Products for Dengue Fever - Comparative Analysis
  • Dengue Fever - Therapeutics under Development by Companies
  • Dengue Fever - Therapeutics under Investigation by Universities/Institutes
  • Dengue Fever - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Dengue Fever - Products under Development by Companies
  • Dengue Fever - Products under Investigation by Universities/Institutes
  • Dengue Fever - Companies Involved in Therapeutics Development
    • Abivax S.A.
    • Agilvax, Inc.
    • Altravax, Inc.
    • Arbovax, Inc.
    • BCI Pharma
    • Bioneer Corporation
    • Biotron Limited
    • CalAsia Pharmaceuticals, Inc.
    • Cocrystal Pharma, Inc.
    • Codagenix, Inc.
    • Emergent BioSolutions Inc.
    • Ennaid Therapeutics, LLC
    • GlaxoSmithKline Plc
    • Globavir Biosciences, Inc.
    • Hawaii Biotech, Inc.
    • Humabs BioMed SA
    • Immunotope, Inc.
    • Immunovaccine, Inc.
    • Inovio Pharmaceuticals, Inc.
    • Johnson & Johnson
    • Kineta, Inc.
    • Merck & Co., Inc.
    • Molplex Ltd.
    • NanoViricides, Inc.
    • Novartis AG
    • NovaTarg Therapeutics, Inc
    • Panacea Biotec Limited
    • ProtInhi B.V.
    • Sanofi Pasteur SA
    • Sarepta Therapeutics, Inc.
    • SIGA Technologies, Inc.
    • Takeda Pharmaceutical Company Limited
    • TechnoVax, Inc.
    • Themis Bioscience GmbH
    • VaxInnate Corporation
    • Visterra, Inc.
  • Dengue Fever - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABX-220 - Drug Profile
    • ABX-221 - Drug Profile
    • Antisense RNAi Oligonucleotide for Dengue - Drug Profile
    • Antisense RNAi Oligonucleotide for Dengue - Drug Profile
    • BRM-211 - Drug Profile
    • CDX-DENV-14 - Drug Profile
    • celgosivir hydrochloride - Drug Profile
    • dengue (tetravalent) vaccine - Drug Profile
    • dengue (tetravalent) vaccine - Drug Profile
    • dengue (tetravalent) vaccine - Drug Profile
    • dengue (tetravalent) vaccine - Drug Profile
    • dengue (tetravalent) vaccine - Drug Profile
    • dengue (tetravalent) vaccine - Drug Profile
    • dengue (tetravalent) vaccine - Drug Profile
    • dengue (tetravalent) vaccine 4 - Drug Profile
    • dengue (tetravalent) vaccines - Drug Profile
    • dengue (virus like particle) vaccine - Drug Profile
    • dengue (virus like particle) vaccine - Drug Profile
    • dengue [serotype 1] vaccine - Drug Profile
    • dengue [serotype 2] (monovalent) vaccine - Drug Profile
    • dengue [serotype 2] vaccine - Drug Profile
    • dengue [serotype 3] (monovalent) vaccine - Drug Profile
    • dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine - Drug Profile
    • dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine - Drug Profile
    • dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine - Drug Profile
    • dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine - Drug Profile
    • dengue [serotypes 1, 2, 3, 4] (tetravalent) virus like particle vaccine - Drug Profile
    • dengue [serotypes 1, 2] vaccine - Drug Profile
    • dengue [serotypes 1, 3, 4] (trivalent) vaccine - Drug Profile
    • dengue vaccine - Drug Profile
    • dengue vaccine - Drug Profile
    • dengue vaccine - Drug Profile
    • dengue vaccine - Drug Profile
    • dengue vaccine - Drug Profile
    • dengue vaccine - Drug Profile
    • DengueCide - Drug Profile
    • DV-2DeltaGVII - Drug Profile
    • DV-2DeltaLIG - Drug Profile
    • DV-2G460P - Drug Profile
    • FDX-000 - Drug Profile
    • fenretinide - Drug Profile
    • FX-06 - Drug Profile
    • GBV-001 - Drug Profile
    • GBV-006 - Drug Profile
    • GREDEN/V1-4 - Drug Profile
    • KIN-1148 - Drug Profile
    • KIN-1400 - Drug Profile
    • LCTA-949 - Drug Profile
    • LVM-142 - Drug Profile
    • modipafant - Drug Profile
    • Monoclonal Antibodies for Dengue - Drug Profile
    • Monoclonal Antibodies to Target Virion, prM and E Proteins for Dengue - Drug Profile
    • Monoclonal Antibody for Dengue - Drug Profile
    • Monoclonal Antibody for Dengue - Drug Profile
    • Peptides for Infectious Diseases - Drug Profile
    • PY-2 - Drug Profile
    • QR-211 - Drug Profile
    • Recombinant Peptide to Inhibit Dengue Protease for Dengue - Drug Profile
    • RKP-00156 - Drug Profile
    • RS-1137 - Drug Profile
    • RS-1142 - Drug Profile
    • RS-1145 - Drug Profile
    • RS-930 - Drug Profile
    • RS-961 - Drug Profile
    • Small Molecule for Dengue - Drug Profile
    • Small Molecule for Dengue - Drug Profile
    • Small Molecule for Dengue - Drug Profile
    • Small Molecule to Inhibit NS2B-NS3 Protease for Dengue and West Nile Virus Infection - Drug Profile
    • Small Molecule to Inhibit NS4B for Dengue and Yellow Fever Virus Infections - Drug Profile
    • Small Molecule to Inhibit RNA Dependent RNA Polymerase for Dengue - Drug Profile
    • Small Molecule to Target Envelope Protein for Dengue - Drug Profile
    • Small Molecules for Dengue - Drug Profile
    • Small Molecules to Activate AMPK for Dengue - Drug Profile
    • Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile
    • Small Molecules to Inhibit Furin for Dengue - Drug Profile
    • Small Molecules to Inhibit M Protein for Dengue - Drug Profile
    • Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile
    • Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
    • Small Molecules to Inhibit Pan Polymerase for Dengue - Drug Profile
    • Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections - Drug Profile
    • Small Molecules to Inhibit Serine Protease for Viral Infections - Drug Profile
    • Small Molecules to Target Envelope Protein for Dengue - Drug Profile
    • ST-148 - Drug Profile
    • ST-324 - Drug Profile
    • ST-610 - Drug Profile
    • Synthetic Peptide for Dengue - Drug Profile
    • Synthetic Peptide for Dengue Virus and West Nile Virus Infections - Drug Profile
    • TAK-003 - Drug Profile
    • TDEN-PIV - Drug Profile
    • TV-003 - Drug Profile
    • TVX-005 - Drug Profile
    • UV-4B - Drug Profile
    • V-180 - Drug Profile
    • Viral PMO-X - Drug Profile
    • VIS-513 - Drug Profile
  • Dengue Fever - Dormant Projects
  • Dengue Fever - Discontinued Products
  • Dengue Fever - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Dengue Fever, H1 2016
  • Number of Products under Development for Dengue Fever - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Dengue Fever - Pipeline by Abivax S.A., H1 2016
  • Dengue Fever - Pipeline by Agilvax, Inc., H1 2016
  • Dengue Fever - Pipeline by Altravax, Inc., H1 2016
  • Dengue Fever - Pipeline by Arbovax, Inc., H1 2016
  • Dengue Fever - Pipeline by BCI Pharma, H1 2016
  • Dengue Fever - Pipeline by Bioneer Corporation, H1 2016
  • Dengue Fever - Pipeline by Biotron Limited, H1 2016
  • Dengue Fever - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2016
  • Dengue Fever - Pipeline by Cocrystal Pharma, Inc., H1 2016
  • Dengue Fever - Pipeline by Codagenix, Inc., H1 2016
  • Dengue Fever - Pipeline by Emergent BioSolutions Inc., H1 2016
  • Dengue Fever - Pipeline by Ennaid Therapeutics, LLC, H1 2016
  • Dengue Fever - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Dengue Fever - Pipeline by Globavir Biosciences, Inc., H1 2016
  • Dengue Fever - Pipeline by Hawaii Biotech, Inc., H1 2016
  • Dengue Fever - Pipeline by Humabs BioMed SA, H1 2016
  • Dengue Fever - Pipeline by Immunotope, Inc., H1 2016
  • Dengue Fever - Pipeline by Immunovaccine, Inc., H1 2016
  • Dengue Fever - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • Dengue Fever - Pipeline by Johnson & Johnson, H1 2016
  • Dengue Fever - Pipeline by Kineta, Inc., H1 2016
  • Dengue Fever - Pipeline by Merck & Co., Inc., H1 2016
  • Dengue Fever - Pipeline by Molplex Ltd., H1 2016
  • Dengue Fever - Pipeline by NanoViricides, Inc., H1 2016
  • Dengue Fever - Pipeline by Novartis AG, H1 2016
  • Dengue Fever - Pipeline by NovaTarg Therapeutics, Inc, H1 2016
  • Dengue Fever - Pipeline by Panacea Biotec Limited, H1 2016
  • Dengue Fever - Pipeline by ProtInhi B.V., H1 2016
  • Dengue Fever - Pipeline by Sanofi Pasteur SA, H1 2016
  • Dengue Fever - Pipeline by Sarepta Therapeutics, Inc., H1 2016
  • Dengue Fever - Pipeline by SIGA Technologies, Inc., H1 2016
  • Dengue Fever - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Dengue Fever - Pipeline by TechnoVax, Inc., H1 2016
  • Dengue Fever - Pipeline by Themis Bioscience GmbH, H1 2016
  • Dengue Fever - Pipeline by VaxInnate Corporation, H1 2016
  • Dengue Fever - Pipeline by Visterra, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Dengue Fever - Dormant Projects, H1 2016
  • Dengue Fever - Dormant Projects (Contd..1), H1 2016
  • Dengue Fever - Dormant Projects (Contd..2), H1 2016
  • Dengue Fever - Dormant Projects (Contd..3), H1 2016
  • Dengue Fever - Dormant Projects (Contd..4), H1 2016
  • Dengue Fever - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Dengue Fever, H1 2016
  • Number of Products under Development for Dengue Fever - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top